Publication date context: February 19 2026. A multicenter clinical study is evaluating an endoscopic implant for adults with type 2 diabetes and obesity. The trial is not yet recruiting and is listed on ClinicalTrials.gov as NCT07417683. Sponsors include Trans Duodenal Concepts GmbH, novineon CRO GmbH and VDI Technologiezentrum. This article summarizes the information available from the trial record and sponsor materials with a view to regulatory context.
What is the study examining?
The research program centers on an endoscopic implant intended to be placed in the duodenal region as part of an approach for managing type 2 diabetes in patients with obesity. The device is described in the trial record as Trans Duodenal Barrier and is under evaluation by a team led by a sponsor group comprising Trans Duodenal Concepts GmbH, novineon CRO GmbH and VDI Technologiezentrum. The study is listed on ClinicalTrials.gov with identifier NCT07417683 and is currently not recruiting.
Who are the parties behind the study?
The primary sponsor is Trans Duodenal Concepts GmbH. The program includes novineon CRO GmbH and VDI Technologiezentrum as collaborators in contract research and technology development. This arrangement signals a focused regulatory pathway in which sponsor statements describe intended use and safety considerations as part of the trial record.
What is the study design and status?
The project is described as a multicenter investigation aimed at gaining early clinical experience with the endoscopic Trans Duodenal Barrier implant. The record notes not yet recruiting and does not present efficacy data.
What is notable about the recruitment and registration?
Recruitment status is Not yet recruiting. The trial appears to be registered in the ClinicalTrials.gov database, providing an identifying number and public accessibility to the protocol and sponsor contact points. This supports ongoing regulatory scrutiny and monitoring obligations under applicable medical device rules.
What device is involved and who is behind it?
The device under study is described as an endoscopic implant intended for trans duodenal deployment. It is developed and supported by Trans Duodenal Concepts GmbH with collaboration from novineon CRO GmbH and VDI Technologiezentrum. The description in the trial record aligns with a regulated research activity rather than a marketing clearance at this stage.
What regulatory signals apply?
As a clinical trial record, the document establishes a regulatory context for evaluating the device rather than presenting performance data or a clearance statement. The reference to an Annex XIV style approach signals attention to intended purpose, safety and performance expectations held by the sponsor. Manufacturer statements are noted in the record as such, and no performance results or formal regulatory authorization are reported at this stage.
What are the next steps and timelines?
The available information does not specify a timeline. The not yet recruiting status implies that additional regulatory steps, site initiation and enrollment planning would follow before any device use outside a regulated investigational setting. Stakeholders should monitor the ClinicalTrials.gov record and sponsor communications for updates.
FAQ
- What is the device called and what is its intended purpose? The endoscopic implant is described as Trans Duodenal Barrier and is under evaluation for adults with type 2 diabetes and obesity.
- Who sponsors the study? Trans Duodenal Concepts GmbH, novineon CRO GmbH and VDI Technologiezentrum.
- What is the recruitment status? Not yet recruiting.
Conclusion
In summary, this multicenter trial outlines an endoscopic Trans Duodenal Barrier device under regulatory study for type 2 diabetes with obesity. No marketing clearance is claimed at this stage, and updates will depend on regulatory submissions and trial progress.
Disclaimer
This information is intended for professionals and is not legal advice. For regulatory decisions please consult the original sources and applicable laws.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07417683?term=medical+device